A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test
Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. As chief business officer and strategy chief for the Broad over a decade-long stretch, he’d worked with all the big names in a scientific discipline that promises to upend the therapeutics field — eventually. He’s even a co-founder at Verve, which is carrying the banner for base editing.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.